Video Experimental Relacionado
Updated: May 12, 2026
07:14
A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
Los agentes farmacológicos selectivos implican a los canales mitocondriales pero no sarcolemiales K (((ATP) en la
T Sato1, N Sasaki, J Seharaseyon
1Institute of Molecular Cardiobiology, Johns Hopkins University, Baltimore, Md, USA.
Circulation
|May 24, 2000
Resumen
Los canales mitocondriales de K (((ATP), no los canales sarcolemáticos de K (((ATP), son los principales efectores de la cardioprotección. Este estudio diferencia la actividad del canal, confirmando los canales mitocondriales.
Área de la Ciencia:
- Fisiología cardiovascular fisiología cardiovascular.
- Electrofisiología Celular Electrofisiología celular
- Farmacología Farmacología.
Sus antecedentes:
- Los canales de potasio (K ((ATP)) sensibles al ATP están implicados en la cardioprotección.
- Se debaten las funciones específicas de los canales mitocondriales (mitoK (((ATP)) y sarcolemiales (surfaceK (((ATP)).
Objetivo del estudio:
- Investigar las distintas funciones de los canales mitoK (ATP) y superficial (ATP) en la cardioprotección.
- Para diferenciar los efectos de los abridores y bloqueadores de canales selectivos.
Principales métodos:
- Utilizó miocitos ventriculares de conejo y un modelo celular de isquemia simulada.
- Efectos examinados de HMR1098 (bloqueador de ATP de la superficie K) y P-1075 (abre ATP de la superficie K).
- Evaluación de los efectos del diazóxido (abriente de mitoK (((ATP)) y del 5-hidroxidecanoato (bloqueador de mitoK (((ATP)).
Principales resultados:
- HMR1098 corrientes superficiales K (((ATP) selectivamente inhibidas.
- P-1075 canales selectivamente activados de la superficie K (((ATP).
- Diazoxide, pero no P-1075, protegido contra el daño celular durante la isquemia simulada.
- El bloqueo del canal MitoK (((ATP) impidió la cardioprotección inducida por el diazoxido y el acondicionamiento previo, mientras que el bloqueo de la superficie K (((ATP) no lo hizo.
Conclusiones:
- Los canales mitocondriales K (((ATP) son los efectores clave de la cardioprotección.
- Los canales sarcolemiales K ((ATP) no parecen mediar la cardioprotección en este modelo.
Videos de Conceptos Relacionados
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:48ATP Synthase: Mechanism
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
01:30The Electron Transport Chain
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...